- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Mallinckrodt gains tax incentives in Singapore
The office of Mallinckrodt’s regional Asia/Pacific headquarters in Singapore has been awarded “business headquarters” status by the Singapore Economic Development Board.Mallinckrodt’s business tax rate will be reduced to 13% from
The office of Mallinckrodts regional Asia/Pacific headquarters in Singapore has been awarded business headquarters status by the Singapore Economic Development Board.
Mallinckrodts business tax rate will be reduced to 13% from 25% for the five years of the status, said Robert Martsching, Mallinckrodt investor spokesman. The business development designation was awarded in recognition of the pharmaceutical and medical imaging companys commitment to regional business growth.
Singapore business development officials say they hope to establish Mallinckrodt as one of the most dynamic and fastest growing healthcare companies in the Asia/Pacific region. Mallinckrodts regional headquarters in Singapore has 34 employees and is headed by Kin Chua, president of Mallinckrodt Asia/Pacific.
Staff members provide marketing, technical, financial, and administrative support to Mallinckrodt offices and employees throughout the Pacific Rim, including Australia, China, Hong Kong, India, Korea, Japan, and Taiwan. Mallinckrodts Singapore office has established a clinical education center to enhance the technical skills of providers, distributors, and employees.
Can AI Facilitate Single-Phase CT Acquisition for COPD Diagnosis and Staging?
December 12th 2024The authors of a new study found that deep learning assessment of single-phase CT scans provides comparable within-one stage accuracies to multiphase CT for detecting and staging chronic obstructive pulmonary disease (COPD).
Assessing MACE Risk in Women: Can an Emerging Model with SPECT MPI Imaging Have an Impact?
December 9th 2024In research involving over 2,200 women who had SPECT MPI exams, researchers found that those who had a high score with the COronary Risk Score in WOmen (CORSWO) model had a greater than fourfold higher risk of major adverse coronary events (MACE).
